Abstract

This new Senior Scientist Award will free-up clinical time at the VA so I can continue my research on treatment outcome studies of persons with substance use disorders. My research career began in 1970 and since that time I have been P.I. on 17 grants and co-investigator on another 20 or more. Over the years my research activities have grown such that they conflict with clinical responsibilities that are necessary to maintain my VA salary, even though 75% of that time is for NIH and VA research. This award will allow me to reduce VA time to 5/8ths and reduce patient care and on-call responsibilities to 6 hours/week. Immediate plans are to continue projects that include 1) the Delaware Valley Node of the Clinical Trials Network (CTN) on which I am P.I. and responsible for 4 protocols: buprenorphine/naloxone for opioid dependent patients aged 14-21, motivational enhancement therapy, motivational incentives, and changes in treatment practices as a result of CTN participation; 2) studies on the long term course of HIV risk behavior among persons in and out of methadone treatment and the effect of methadone on immune function; 3) VA studies of patients who dropped out or were suspended from methadone treatment and of """"""""Seeking Safety"""""""", a group therapy for veterans with substance use disorders and PTSD; and 4) studies in St. Petersburg, Russia comparing naltrexone with or without fluoxetine for relapse prevention and HIV risk reduction and of comorbidities between HIV, hepatitis B and C, TB and alcohol and drug dependence. Long term plans are to 1) submit a competing renewal of CTN studies in the Fall of '03; 2) implement a study of depot vs oral naltrexone in St. Petersburg; 3) help investigators in St. Petersburg and Porto Alegre, Brazil develop Centers for HIV prevention, treatment and research; and 4) submit a pilot study of buprenorphine for heroin addiction treatment of HIV+ and HIV- patients in Kiev, Ukraine. This work will be done at the University of Pennsylvania/Philadelphia VAMC Addiction Treatment Research Center, the Treatment Research Institute, and the Penn Center for AIDS Research where I have been an active participant since their beginnings.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Scientist Award (K05)
Project #
5K05DA017009-02
Application #
6799759
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Montoya, Ivan
Project Start
2003-09-10
Project End
2008-08-31
Budget Start
2004-09-01
Budget End
2005-08-31
Support Year
2
Fiscal Year
2004
Total Cost
$126,554
Indirect Cost

  Institution

Name
University of Pennsylvania
Department
Psychiatry
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104

  Publications

Poole, Sabrina A; Pecoraro, Anna; Subramaniam, Geetha et al. (2016) Presence or Absence of QTc Prolongation in Buprenorphine-Naloxone Among Youth With Opioid Dependence. J Addict Med 10:26-33
Krupitsky, Evgeny; Zvartau, Edwin; Blokhina, Elena et al. (2016) Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant. Am J Drug Alcohol Abuse 42:614-620
Woody, George E; Krupitsky, Evgeny; Zvartau, Edwin (2016) Antagonist Models for Relapse Prevention and Reducing HIV Risk. J Neuroimmune Pharmacol 11:401-7
Piralishvili, Gvantsa; Otiashvili, David; Sikharulidze, Zura et al. (2015) Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia. J Subst Abuse Treat 50:32-7
Rawson, Richard A; Woody, George; Kresina, Thomas F et al. (2015) The globalization of addiction research: capacity-building mechanisms and selected examples. Harv Rev Psychiatry 23:147-56
Dvoriak, Sergii; Karachevsky, Andrey; Chhatre, Sumedha et al. (2014) Methadone maintenance for HIV positive and HIV negative patients in Kyiv: acceptability and treatment response. Drug Alcohol Depend 137:62-7
Woody, George E; Bruce, Douglas; Korthuis, P Todd et al. (2014) HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. J Acquir Immune Defic Syndr 66:288-93
Pecoraro, Anna; Ewen, Edward; Horton, Terry et al. (2014) Using the AUDIT-PC to predict alcohol withdrawal in hospitalized patients. J Gen Intern Med 29:34-40
Woody, George; Bruce, Douglas; Korthuis, P Todd et al. (2014) Authors' reply: ""Risk reduction with buprenorphine-naloxone and methadone: patient's choice"". J Acquir Immune Defic Syndr 67:e142-3
Mannelli, Paolo; Wu, Li-Tzy; Peindl, Kathleen S et al. (2014) Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial. Drug Alcohol Depend 138:83-8

Showing the most recent 10 out of 50 publications